UPM Pharmaceuticals, a Baltimore, Maryland-based drug development and contract manufacturer, will be acquiring the 500,000-ft2 commercial manufacturing facility that Pfizer currently operates in Bristol, Tennessee.
The acquisition of the Pfizer facility will provide UPM with large-scale commercial capabilities for manufacturing and packaging of solid oral dosage tablets and capsules as well as semisolid manufacturing of creams and ointments. The facility will also provide for technology-transfer support, pilot-plant scale-up capabilities, analytical and microbial testing as well as dedicated suites for potent compounds. As part of the purchase, UPM will continue to manufacture Pfizer’s current portfolio of products within the facility for two years. The new facility will give UPM the capability to annually produce 3.5 billion tablets and 680 million capsules.
Pfizer gained the facility as part of its acquisition of King Pharmaceuticals, a deal which was announced in late 2010 and completed in early 2011. King Pharmaceuticals was founded by UPM’s current Chairman and CEO John Gregory.